Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare


As a participant in the lifesciences and healthcare industry, you know that discovery and innovation are key to finding lasting health solutions. Yet due to the highly regulated nature of the industry, you - a corporate, investor or start-up - must overcome complex administrative, compliance and liability hurdles before your products and services can come to market.

With more than 300 lawyers, patent attorneys, scientists and academics across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics.

With active memberships in the major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day to day operational needs such as support with public sector procurement, patent prosecution and enforcement, commercial agreements, tax and transfer pricing, and regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less
Ex­pect­a­tion of a Faster Growth of Health Food in Near Fu­ture
The Ad­min­is­trat­ive Meas­ures for the Re­gis­tra­tion and Re­cordal of Health Food (“Meas­ures”) ad­op­ted and pro­mul­gated by China Food and Drug Ad­min­is­tra­tion ("CF­DA") on 4 Feb­ru­ary 2016 have come in­to force on 1 Ju­ly 2016.The above Meas­ures give more clari
New GCP of Med­ic­al Devices
On 23 March 2016, the China Food and Drugs Ad­min­is­tra­tion (“CF­DA”) and Na­tion­al Health and Fam­ily Plan­ning Com­mis­sion (“NHFPC”) jointly is­sued the new Good Clin­ic­al Prac­tice of Med­ic­al Devices (“New GCP”). This New GCP will re­place the Pro­vi­sions on
China En­cour­ages In­nov­at­ive Drug by Modi­fy­ing Its Drug Clas­si­fic­a­tion Rules
Fol­low­ing the new rules of clas­si­fic­a­tion of med­ic­al devices ef­fect­ive as of 1st Janu­ary 2016, the China Food and Drug Ad­min­is­tra­tion (“CF­DA”) is­sued a cir­cu­lar re­gard­ing the re­form of chem­ic­al drug re­gis­tra­tion clas­si­fic­a­tion on 4 March 2016 (“Cir­cu


Show only
15 September 2020
On the Pulse
A video/pod­cast series, On the Pulse, brings to­geth­er CMS ex­perts to dis­cuss key top­ics im­pact­ing, in­nov­at­ing, dis­rupt­ing the life sci­ence & health­care sec­tor.
20 April 2020
CMS Ex­pert Guide to ad­vert­ising of medi­cines and med­ic­al devices
Are you look­ing for in­form­a­tion on phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising? Learn more about it in this CMS Ex­pert Guide.
13 August 2020
Over­view on Key Is­sues of the Tort Li­ab­il­ity Part of Chin­a's First Civil...
The People’s Re­pub­lic of China’s (“PRC”) first com­bined co­di­fic­a­tion of the civil law ever, i.e. the PRC Civil Code (“PRC Civil Code”) which was ad­op­ted on 28 May 2020 and which will enter...
Over­view on Key Is­sues of the Con­tract Part of China’s First Civil Code
13 August 2020
Sus­tain­able food pro­gress may close glob­al reg­u­lat­ory gap
In­nov­a­tion in the sus­tain­able food sec­tor is for­ging ahead at a re­mark­able pace. Our cur­rent food sources ac­count for nearly one-third of glob­al GHG emis­sions while con­sumers are in­creas­ingly bet­ter edu­cated...
Over­view on the Stip­u­la­tions on Prop­erty Rights in China’s First Civil...
04 August 2020
China Tax Reg­u­la­tion Up­date - Ju­ly 2020
The latest de­vel­op­ment in China Tax Reg­u­la­tion mainly in­cludes: Caishui [2020] No. 31 jointly re­leased by the Min­istry of Fin­ance (“MOF”) and the State Ad­min­is­tra­tion of Tax­a­tion (“SAT”)...
Out­look on the New Stand­ards of Good Man­u­fac­tur­ing Prac­tice for Veter­in­ary...
15 July 2020
China pub­lishes 2nd draft of amend­ment to pat­ent law
On 3 Ju­ly 2020, the second draft of the Amend­ment to the Pat­ent Law of the People’s Re­pub­lic of China was pub­lished. Dif­fer­ent from the first draft pub­lished in early 2019, this second draft in­cludes...
Na­tion­al People's Con­gress Ad­opts China’s First Civil Code
08 July 2020
“WIPO PROOF”: WIPO’s new on­line ser­vice which helps in­nov­at­ors and cre­at­ors...
The World In­tel­lec­tu­al Prop­erty Or­gan­isa­tion (WIPO) re­cently launched its new on­line busi­ness ser­vice, “WIPO PROOF”. The plat­form aims to help in­nov­at­ors and cre­at­ors safe­guard their in­tel­lec­tu­al...
High­lights on the Re­vised Drug Re­gis­tra­tion Ad­min­is­trat­ive Meas­ures